Virbac S.A.

Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
  • TickerVIRP
  • ISINFR0000031577
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

1 director sold

A director at Virbac sold 3,179 shares at 230.708EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board member...

Alfred Glaser ...
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hana Maalej
  • Nicolas Thorez
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 17/10/2019

...

Emmanuel Matot

Manutan International : Postviews résultats S1 S&M Caps : croissance et levier au rendez-vous

>Poursuite d’une croissance soutenue de l’activité au T2 – Pas encore d’impact des tensions géopolitiques - Nous disposons dorénavant de l’ensemble des publications S1 des sociétés S&M Caps en France. La première bonne nouvelle est que la croissance des CA est restée soutenue au T2 (+8.8% en moyenne), peu éloignée du T1 (+10.2%) et légèrement supérieure à nos attentes (+8.0%). Les tensions géopolitiques ne se sont donc pas encore matérialisées au niveau de l’activité,...

Emmanuel Matot

Manutan International : Postviews résultats S1 S&M Caps : croissance et levier au rendez-vous

>Poursuite d’une croissance soutenue de l’activité au T2 – Pas encore d’impact des tensions géopolitiques - Nous disposons dorénavant de l’ensemble des publications S1 des sociétés S&M Caps en France. La première bonne nouvelle est que la croissance des CA est restée soutenue au T2 (+8.8% en moyenne), peu éloignée du T1 (+10.2%) et légèrement supérieure à nos attentes (+8.0%). Les tensions géopolitiques ne se sont donc pas encore matérialisées au niveau de l’activité,...

Emmanuel Matot

Manutan International : H1 reporting season postview S&M caps: growth and leverage as expected

>Continuation of robust sales growth in Q2 - Geopolitical tensions yet to make an impact - We now have all of the H1 publications for S&M cap companies in France. The first piece of good news is that sales growth remained robust in Q2 (+8.8% on average), relatively close to Q1 (+10.2%) and a shade above our forecasts (+8.0%). Geopolitical tension therefore had yet to have an impact on the level of business during the spring, which also benefited from a favourable €/$ ...

Christophe-Raphaël Ganet

Virbac : Good Q3 sales figures (sequential improvement) – guidance upgraded – forecasts and target price (€ 229 vs € 212) revised upwards

>Solid growth despite the comps - Q3 sales came in at € 233.6m, up 14.3% (+12.2% l-f-l). In terms of the ranges, growth stemmed mainly from products for the domestic pets segment (dental, parasiticide, petfood and specialty ranges). Products for cattle such as vaccines and nutritional supplements and parasiticide and aquaculture products “contributed to the Q3 performance”.For nine months, sales came to €697.3m (+9.9% and +8.4% l-f-l).On the basis of th...

Christophe-Raphaël Ganet

Virbac : Bon CA T3 (accélération séquentielle) – Guidances relevées – Prévisions et OC (229 € vs 212 €) relevés

>Croissance solide malgré l’effet de base - Le CA T3 ressort à 233.6 M€, en hausse de 14.3% (+12.2% à tcc.). Au plan des gammes, la croissance provient essentiellement des produits du segment des animaux de compagnie (gammes dentaire, antiparasitaires, petfood et spécialités). Les produits à destination des bovins tels que les vaccins et les compléments nutritionnels, et les produits antiparasitaires d’aquaculture « participent à la performance du trimestre ».§rc...

Christophe-Raphaël Ganet

Virbac : Feedback from road show: looking beyond the recovery alone

>H1 2019: a first indicator of the group’s potential - Virbac unveiled favourable interim results (underlying operating profit : +48% - net earnings : +125%), giving a significant increase of 400bp in the operating margin, or around +300bp excluding one-off items, and an increasingly healthy balance sheet (leverage: 3x vs covenant of 3.75x at end-2019). These figures emphasise the good execution of the recovery plan - margins better than expected, especially with good...

1 director sold

A director at Virbac sold 3,179 shares at 230.708EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board member...

Alfred Glaser ...
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hana Maalej
  • Nicolas Thorez
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 17/10/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Hana Maalej

ODDO BHF Small & MIDCAP MORNING NEWS - 10/14/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Hana Maalej

ODDO BHF Small & MIDCAP MORNING NEWS - 14/10/2019

...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier
  • Martial Descoutures
  • Nicolas David
  • Nicolas Thorez
  • Oussema Denguir
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 09/24/2019

...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier
  • Martial Descoutures
  • Nicolas David
  • Nicolas Thorez
  • Oussema Denguir
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 24/09/2019

...

VIRBAC sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of VIRBAC (FR), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date August 6, 2019, the closing price was EUR 167.40 and its potential was estimated at EUR 195.49.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Zoetis Inc - Strategy, SWOT and Corporate Finance Report

Summary Zoetis Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. KeyHighlights Zoetis Inc (Zoetis) is a global animal health company. It discovers, develops, manufactures and commercializes animal health medicines and vaccines with a focus on livestock and companion animals. The company offers anti-infective products, vaccines, parasiticides and medicated feed additives amon...

MarketLine Department

Zoetis Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Zoetis Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Zoetis Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights ...

Pauline Delecourt

Virbac 18 juin 2019

Tout d’abord, Proxinvest regrette que les rémunérations de chacun des membres du Directoire soient regroupées au sein d’une même résolution (résolution 13). En raison du regroupement des rémunérations au sein d’une même résolution, de l’absence de communication des taux de réalisation et des objectifs à atteindre et une hausse significative des bonus nous ne soutiendrons pas la résolution 13. De même, en raison de ce manque de transparence Proxinvest recommande de s'opposer aux résolutions 14 et 15, relatives aux rémunérations des dirigeants pour le nouvel exercice. En raison d’un faible tau...

Jehanne Leroy

Etude de l'AG du 23/06/2017

Proxinvest regrette principalement le manque de transparence de la communication de la société concernant les rémunérations des dirigeants mandataires sociaux. C'est, en effet, en raison de ce manque de transparence que Proxinvest recommande de s'opposer aux résolutions 8 à 12, relatives aux rémunérations des dirigeants. Proxinvest regrette par ailleurs que la société maintienne la possibilité de l'usage de ces autorisations financières en période d'offre publique, en raison de leur possible utilisation comme arme anti-OPA. Proxinvest considère en effet que les OPA sont des opportunités d'enr...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Defensive posture warranted Our outlook for global equity markets remains cautious and we expect additional weakness and consolidation, notwithstanding shorter-term countertrend rallies. Indexes throughout Europe and Asia continue their struggle to gain a firm footing, and, unsurprisingly, the same can be said of broad developed and emerging market indexes (i.e., MSCI EAFE, EM, ACWI, ACWI ex-U.S.) which are all in downtrends or have recently broken down. In light of continued global market weakness, we believe a defensive posture is warranted. In today's report we highlight various ways to ac...

Valérie GASTALDY

Short term view - VIRBAC SA : The movement can go on.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at €152.70 and €157.00. The trend would be invalidated below the support at €138.60.

Valérie GASTALDY

Analyse court terme - VIRBAC SA : Le mouvement peut se poursuivre.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 152,70 € et 157,00 €. La tendance serait invalidée sous le support à 138,60 €.

Valérie GASTALDY

Short term view - VIRBAC SA : The background trend is clearly bullish.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at €152.70 and €157.00. The trend would be invalidated below the support at €138.60.

Valérie GASTALDY

Analyse court terme - VIRBAC SA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 152,70 € et 157,00 €. La tendance serait invalidée sous le support à 138,60 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch